Author

E. Arthofer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1

Frequent Co-Authors

K. Chakraborty· 3 shared M. Choudhry· 3 shared T. Henley· 3 shared D. H. Barouch· 2 shared A. Chandrashekar· 1 shared A. Sidaway· 1 shared B. R. Webber· 1 shared B. S. Moriarity· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

K. Chakraborty

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A Novel CRISPR-Engineered, Stem Cell-Derived Cellular Vaccine

K. Chakraborty, A. Chandrashekar, A. Sidaway, E. Latta, J. Yu, K. McMahan, C. Manickam, K. Kroll, M. Mosher, R. K. Reeves, R. Gam, E. Arthofer, M. Choudhry, D. H. Barouch, T. Henley

This paper describes a CRISPR-engineered cellular vaccine designed to mimic natural immunity, showing robust neutralizing antibody responses and reduced viral load in non-human primates.

bioRxiv · Dec 28, 2021 · PreprintImmunology

Genetic editing of CISH enhances T cell effector programs independently of immune checkpoint cell surface ligand expression

E. Arthofer, K. Chakraborty, L. Viney, M. J. Johnson, B. R. Webber, B. S. Moriarity, E. Lou, M. Choudhry, C. A. Klebanoff, T. Henley

This study shows that genetic editing of CISH enhances T cell anti-tumor activity independently of PD-L1 expression, outperforming PD-1 and TIGIT disruption in certain contexts.

bioRxiv · Aug 17, 2021 · PreprintCancer Biology

A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL)

R. Sivapalan, J. Liu, K. Chakraborty, E. Arthofer, M. Choudhry, P. S. Barie, D. H. Barouch, T. Henley

This paper describes a method to generate virus-specific T cells from convalescent patients using artificial antigen presenting cells and rapid expansion, showing their potential as an adoptive cell therapy for COVID-19 and other viral infections.

bioRxiv · Nov 26, 2020Immunology